Aclaris Therapeutics Inc. (NASDAQ:ACRS) saw unusually-high trading volume on Thursday . Approximately 85,722 shares were traded during mid-day trading, an increase of 13% from the previous session’s volume of 75,592 shares.The stock last traded at $21.02 and had previously closed at $20.75.

ACRS has been the subject of several research reports. Jefferies Group reiterated a “buy” rating and issued a $20.00 target price on shares of Aclaris Therapeutics in a research report on Sunday, March 27th. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 24th. Finally, Guggenheim initiated coverage on shares of Aclaris Therapeutics in a research report on Friday, June 10th. They issued a “buy” rating and a $35.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $28.50.

The firm’s market capitalization is $424.81 million. The firm has a 50 day moving average of $19.75 and a 200-day moving average of $19.48.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by $0.15. On average, analysts anticipate that Aclaris Therapeutics Inc. will post ($2.45) EPS for the current fiscal year.

An institutional investor recently bought a new position in Aclaris Therapeutics stock. Turner Investments L.P. acquired a new stake in shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) during the fourth quarter, according to its most recent filing with the SEC. The institutional investor acquired 57,694 shares of the company’s stock, valued at approximately $1,554,000. Turner Investments L.P. owned 0.29% of Aclaris Therapeutics as of its most recent filing with the SEC.

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.